JelikaLite (Seed)

Funding Details
Awarder
StartEngine
Date Award
June 13, 2024
Vertical
Healthcare
Funding URL
View Funding Page
Premoney Valuation
$1,000,000
Valuation
$11,050,000

Company Info
Founding Year
Not provided in the memo
Traction
JelikaLite has completed a Phase I placebo-controlled clinical trial of its prototype, showing statistically significant improvement in children who received the treatment. The company has also received a Breakthrough Device Designation from the FDA for its Cognilum system.
Organizations Involved
None
Founders
Eugenia Steingold, Katya Sverdlov, Luis DeTaboada
Company Description
JelikaLite is focused on developing Cognilum, a medical solution aimed at reducing autism symptoms in children through noninvasive brain stimulation using near-infrared light, EEG sensors, and an AI personalization platform. The company aims to provide a personalized, home-based treatment option for children with autism, addressing the limitations of current therapies and medications.
Market
Autism Treatment
Location
New York, NY, US
Coinvestors
None

Links
Back to Home Back to Healthcare Deals View Funding Announcement